Corcept Therapeutics (NASDAQ:CORT) Sets New 52-Week High After Analyst Upgrade
Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) hit a new 52-week high during trading on Tuesday after Canaccord Genuity Group raised their price target on the stock from $130.00 to $142.00. Canaccord Genuity Group currently has a buy rating on the stock. Corcept Therapeutics traded as high as $117.33 and last traded at $114.22, […]
Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) hit a new 52-week high during trading on Tuesday after Canaccord Genuity Group raised their price target on the stock from $130.00 to $142.00. Canaccord Genuity Group currently has a buy rating on the stock. Corcept Therapeutics traded as high as $117.33 and last traded at $114.22, […]
